Baxalta Inc (BXLT) : Krensavage Asset Management reduced its stake in Baxalta Inc by 0.47% during the most recent quarter end. The investment management company now holds a total of 734,885 shares of Baxalta Inc which is valued at $31.2 Million after selling 3,480 shares in Baxalta Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Baxalta Inc makes up approximately 11.40% of Krensavage Asset Management’s portfolio.
Other Hedge Funds, Including , Dimensional Fund Advisors Lp boosted its stake in BXLT in the latest quarter, The investment management firm added 24,521 additional shares and now holds a total of 976,378 shares of Baxalta Inc which is valued at $41.4 Million. Baxalta Inc makes up approx 0.03% of Dimensional Fund Advisors Lp’s portfolio.Kings Point Capital Management reduced its stake in BXLT by selling 417 shares or 39.6% in the most recent quarter. The Hedge Fund company now holds 636 shares of BXLT which is valued at $26,960. Baxalta Inc makes up approx 0.01% of Kings Point Capital Management’s portfolio.Wheatland Advisors Inc reduced its stake in BXLT by selling 1,300 shares or 2.74% in the most recent quarter. The Hedge Fund company now holds 46,209 shares of BXLT which is valued at $2 Million. Baxalta Inc makes up approx 1.06% of Wheatland Advisors Inc’s portfolio.Skba Capital Management reduced its stake in BXLT by selling 53,900 shares or 14.22% in the most recent quarter. The Hedge Fund company now holds 325,060 shares of BXLT which is valued at $13.8 Million. Baxalta Inc makes up approx 1.37% of Skba Capital Management’s portfolio.Ngam Advisors boosted its stake in BXLT in the latest quarter, The investment management firm added 1,708 additional shares and now holds a total of 29,246 shares of Baxalta Inc which is valued at $1.2 Million. Baxalta Inc makes up approx 0.02% of Ngam Advisors’s portfolio.
Baxalta Inc opened for trading at $45.48 and hit $45.71 on the upside on Wednesday, eventually ending the session at $45.71, with a gain of 1.58% or 0.71 points. The heightened volatility saw the trading volume jump to 1,26,92,805 shares. Company has a market cap of $31,245 M.
On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Investors should note that on May 10, 2016, Baxalta Inc announced a cash dividend of $0.0700. The company’s management has announced Jun 8, 2016 as the ex-dividend date and fixed the record date on Jun 10, 2016. The payable date has been fixed on Jul 1, 2016.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.